Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy

Systemic delivery of adeno-associated virus vector expressing gamma-sarcoglycan and the treatment of muscular dystrophy

US Patent 11925675 · Granted Mar 12, 2024

Estimated economic value: $202,924,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Adeno-associated virus vector delivery of muscle specific micro-dystrophin to tr2025
Guide RNA for repairing a mutant human titin gene using CRISPR technology2025
Adeno-associated virus antibodies and fragments thereof2025
Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of mus2025
Self-complementary adeno-associated virus vector and its use in treatment of mus2025
Gene therapy for limb-girdle muscular dystrophy type 2C2025
Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of2025
Methods of treating muscular dystrophy2023
Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dys2023
Repairing a mutant human titin gene using CRISPR technology2023
Adeno-associated virus vector delivery of muscle specific micro-dystrophin to tr2022
Adeno-associated virus antibodies, fragments thereof and encoding polynucleotide2022